Business Wire

Celltrion Healthcare Showcases Positive Data on Switching and Monotherapy With Remsima ® SC in Patients With Inflammatory Bowel Disease at UEG Week Virtual 2021

Share

Celltrion Healthcare today announced two data sets relating to the use of the subcutaneous formulation of infliximab, Remsima® SC (CT-P13 SC), in inflammatory bowel disease (IBD) at a poster presentation at United European Gastroenterology (UEG) Week 2021, held virtually from October 3- 5.

The first study investigated clinical impact of switching from intravenous (IV) to subcutaneous (SC) treatment of infliximab in patients with Crohn’s disease (CD) or ulcerative colitis (UC) from the pivotal randomised controlled trial of CT-P13 SC.3 65 patients (25 CD patients, 40 UC patients) were included in the CT-P13 IV arm in which patients received CT-P13 5 mg/kg IV every 8 weeks from week 6 until week 22. At week 30, patients switched to receive CT-P13 SC every 2 weeks up to week 54 (dose 120 mg or 240 mg for patients < 80 kg or ≥ 80 kg, respectively).1

Results showed switching from IV to SC infliximab conferred more favourable clinical outcomes in terms of pharmacokinetics, efficacy, and possibly, immunogenicity. There was a significant difference in Ctrough pre- and post-switch (median Ctrough Levels at 2.05 μg/mL (interquartile range [IQR], 0.10-3.61) and 21.10 μg/mL (IQR, 11.30-26.50) pre- and post-switch, respectively; p<0.0001). The proportion of patients with Ctrough exceeding target exposure (5 μg/mL) was significantly higher post-switch (36/41, 87.80%) than pre-switch (8/41, 19.51%; p<0.00001). In terms of efficacy, clinical response rates were comparable at both pre- and post-switch timepoints (40/49 [81.63%] vs 44/49 [89.80%], respectively; p=0.3873). However, faecal calprotectin (FC) levels were significantly lower post-switch compared with pre-switch. Anti-drug antibody (ADA) and neutralising antibody (NAb) positivity were also numerically lower post-switch although statistical significance was not reached.1

The second study presented investigated comparable efficacy of subcutaneous (SC) infliximab monotherapy versus combination therapy with immunomodulators using data from the pivotal randomised controlled trial of CT-P13 SC in active CD or UC.3

Patients with active CD or UC who were tumour necrosis factor (TNF) inhibitor treatment–naïve were enrolled and received induction therapy with CT-P13 5 mg/kg intravenously (IV) at week 0 and week 2, after which they were randomised to continue therapy with CT-P13 IV or receive CT-P13 SC 120 mg (patients<80 kg) or 240 mg (patients ≥80 kg) every 2 weeks from week 6 to week 54. Of 66 patients, 37 and 29 received monotherapy and combination therapy, respectively. The results show there was no significant difference between groups in the number of patients with Ctrough level exceeding target exposure with both groups exceeding target exposure throughout the study period (target exposure: 5 μg/mL; monotherapy: 28/29, 96.55%; combination therapy: 23/24, 95.83%; p>0.9999). Clinical response rates in terms of CDAI-100 and partial Mayo response were comparable between arms and there was no difference in immunogenicity between the groups despite the concomitant use of immunomodulators in the combination therapy group.2

Professor Walter Reinisch, Director of Clinical IBD Study Group, Department of Gastroenterology and Hepatology, Medical University of Vienna and the presenting author of the poster presentation said, “The post-hoc analysis indicates that switching from IV to SC infliximab will deliver comparable clinical outcomes for patients with inflammatory bowel disease, including those with Crohn's disease and ulcerative colitis, further highlighting the potential of SC infliximab as an alternative administration route. Infliximab SC offers patients and caregivers the possibility of more convenient care with the potential for in-home use.”

Professor Shomron Ben-Horin, MD, Department of Gastroenterology, Chaim Sheba Medical Center in Israel, and the presenting author of the poster presentation said, “These exploratory results suggest that SC infliximab monotherapy may provide comparable clinical outcomes and immunogenicity to combination therapy with immunomodulators, thereby advancing the concept of SC infliximab monotherapy as a viable treatment option for IBD patients.”

- ENDS -

Notes to Editors:

About inflammatory bowel disease

Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic disabling gastrointestinal disorders that impact every aspect of a patient’s life.4 They affect an estimated 5 million people globally.5 IBDs account for substantial costs to the healthcare system and society - the direct healthcare costs of IBDs are estimated to be €4.6-5.6 billion per year.6

About CT-P13 (biosimilar infliximab)

CT-P13 is developed and manufactured by Celltrion, Inc. and was the world’s first monoclonal antibody biosimilar approved by the European Commission (EC). It is indicated for the treatment of eight autoimmune diseases including Rheumatoid Arthritis (RA) and IBD. It was approved by the EC under the trade name Remsima® in September 2013 and launched in major EU countries in early 2015. The US FDA approved CT-P13 in April 2016 under the trade name Inflectra®. CT-P13 is approved in more than 97 countries (as of September 2021) including the US, Canada, Japan and throughout Europe.

About Remsima® (CT-P13) intravenous (IV) formulation7

Remsima® IV is usually given as 3 mg per kg/body weight in rheumatoid arthritis (RA) and as 5 mg per kg/body weight for the other indications. Infliximab IV is given as an infusion over two hours. All patients are monitored for any reactions during the infusion and for at least one to two hours afterwards.

About Remsima® CT-P13 subcutaneous (SC) formulation

A 120 mg fixed dose of Remsima® SC has been granted marketing authorisation in the EU, in adults regardless of body weight, in all previously approved indications in adult for the IV formulation. Remsima® SC has three available devices; via a pre-filled pen (auto injector), pre-filled syringe or pre-filled syringe with needle safeguard.7 The SC formulation has the potential to enhance treatment options for the use of infliximab by providing high consistency in drug exposure and a convenient method of administration.

About Celltrion Healthcare

Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information please visit: https://www.celltrionhealthcare.com

References

1 Stefan Schreiber, et al. Switching from intravenous to subcutaneous infliximab in patients with active inflammatory bowel disease: Post-hoc analysis of pre-/post- switch outcomes from a multicentre, randomised controlled pivotal trial. Poster (P0472). Presented at UEG Week Virtual 2021.

2 Geert D’Haens, et al. Comparison of combination subcutaneous infliximab and an immunomodulator versus subcutaneous infliximab monotherapy: Post-hoc analysis of a randomised clinical trial. Poster (P0467). Presented at UEG Week Virtual 2021.

3 Schreiber S, et al. Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease. Gastroenterology. 2021; 160:2340-2353

4 Molodecky, N. A, et al. (2012). Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology, 142(1), 46-54. Retrieved from: www.gastrojournal.org/article/S0016-5085(11)01378-3/pdf [Last accessed September 2021].

5 The European Federation of Crohn’s & Ulcerative Colitis Associations. What is IBD? Science. Retrieved from www.efcca.org/en/science [Last accessed September 2021].

6 Burisch. J, et al. (2013). The burden of inflammatory bowel disease in Europe. Journal of Crohn's and Colitis, 7(4), 322-337.Retrieved from: https://www.sciencedirect.com/science/article/pii/S1873994613000305?via%3Dihub [Last accessed September 2021].

7 European Medicines Agency Summary of Product Characteristics (SmPC). Infliximab. Available at https://www.ema.europa.eu/en/documents/product-information/remsima-epar-product-information_en.pdf [Last accessed September 2021].

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information please contact:

Holly Barber
hbarber@hanovercomms.com
+44 (0) 7759 301620

Donna Curran
dcurran@hanovercomms.com
+44 (0) 7984 550312

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IFF to Release Third Quarter 2021 Results November 828.10.2021 22:15:00 CEST | Press release

IFF (NYSE:IFF), today announced that it will release its third quarter 2021 earnings results following the market close on Monday, November 8. The management team will host a live webcast on Tuesday, November 9, 2021 at 10:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do mo

Norsk Titanium Announces Deployment of RPD Builder™ Tool28.10.2021 18:54:00 CEST | Press release

Norsk Titanium AS (Norsk Titanium; Euronext: NTI), a global leader in Directed Energy Deposition (DED) additive manufacturing of aerospace-grade structural titanium components, announces today a significant advancement to their Rapid Plasma Deposition® (RPD®) process. The company has successfully deployed and validated the internally developed RPD Builder™ computer-aided manufacturing tool for the first time, significantly shortening part development timelines. “This is a tremendous accomplishment for Norsk Titanium,” said Nicholas Mayer, Norsk Titanium’s Vice President of Commercial. “RPD Builder™ is a significant enabler as we move into more industrial manufacturing and engineering services markets. It will give our customers added flexibility and allow them to explore part design options independent from our manufacturing engineering team.” RPD Builder™ has been developed over the past three years and incorporates the full knowledge base of Norsk Titanium’s process metallurgy and ma

FINVASIA Acquires Gini Health, Expands Into Healthcare Services28.10.2021 18:49:00 CEST | Press release

FINVASIA, today, announced its investment in Gini Health, a Canada based healthcare technology company that pioneered DNA and lifestyle data based personalized health to prevent diseases. This acquisition furthers FINVASIA’s strategic business objectives of investing in traditional business and transforming them. The partnership supports FINVASIA’s commitment to health care to accelerate technology-led innovation in preventive and personalized healthcare services. Effective immediately, all the previous investors have exited, making FINVASIA and Gini Health’s founder and CEO Gurjot Narwal key stakeholders in the company. This move by FINVASIA is a step towards making the company’s capital structure lean, providing them more room to support their business strategy. Gini Health’s founder and CEO Gurjot Narwal will keep leading the company. Finvasia along with the investment will provide group resources, operational experience, technology, infrastructure, and its reach as a multidisciplin

Philippine Airlines Boosts Digital Transformation by Switching to Rimini Street Support for its Oracle Footprint28.10.2021 18:00:00 CEST | Press release

Rimini Street, Inc. (NASDAQ: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that Philippine Airlines (PAL), the flagship carrier of the Philippines, has switched to Rimini Street Support for its Oracle E-Business Suite, Fusion Middleware and Database software portfolio. The airline made a strategic decision to move to Rimini Street to help it address the challenges faced by the commercial aviation sector as a result of the global pandemic. By turning over complete support of its Oracle footprint, the airline was able to accelerate key digital innovation projects that support the growth of its business including modernizing its cargo system, integrating its mobile and remote capabilities for more efficiencies and launching its passenger analytics for improving its Know Your Customer program. This press release features multimedia. View the full

Verimatrix Video Protection To Be Deployed Inside New WISI Professional ABR Receiver for Hospitality Networks28.10.2021 17:55:00 CEST | Press release

Regulatory News: Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, and WISI, a world leader in edge video delivery solutions, today announced that Verimatrix video protection technologies are set to be deployed within the new WISI Professional ABR Receiver that enables video operators to connect multiscreen PayTV offerings to the edge while still maintaining existing infrastructure at hospitality sites. Designed to allow video operators that service the world’s major hospitality organizations to avoid costly upgrades, WISI’s Professional ABR (Adaptive Bitrate Streaming) Receiver, along with Verimatrix’s protection technologies, eliminate the need for new set-top boxes or TVs. “By providing operators with a simple path toward migrating to ABR services while still supporting Linear TV deployments at the edge, this WISI-Verimatrix solution stands as a notable example of how close industry collaboration can translate into ma

Ben Cousins Appointed Head of Studio Operations for FunPlus’ European Studios28.10.2021 17:00:00 CEST | Press release

FunPlus, a leading independent mobile game developer and publisher, announced today that Ben Cousins has been appointed Head of Studio Operations, supervising projects in development at FunPlus’ studios in Moscow and Stockholm. Based in Stockholm, and in close collaboration with studio leadership in both locations, Cousins will help to optimize the studios’ working environment and align all studio activities to contribute to successful product development and continued company growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211028005417/en/ Ben Cousins Appointed Head of Studio Operations for FunPlus’ European Studios; Free-to-play and games-as-a-service expert brings more than two decades of experience to the role (Photo: Business Wire) A game industry thought leader, Cousins created Battlefield Heroes, one of the western world’s first free-to-play games. A former Executive Producer of the Battlefield franchise at DIC

Moody’s ESG Solutions’ Climate on Demand tool selected by the Private Infrastructure Development Group28.10.2021 16:02:00 CEST | Press release

Moody’s ESG Solutions announced today that the Private Infrastructure Development Group (PIDG) has selected Moody’s Climate on Demand scoring tool to assess climate risk exposure in its investment projects. PIDG mobilizes private investment in sustainable and inclusive infrastructure in sub-Saharan Africa and south and south-east Asia. It will use Moody’s data to screen potential new investments for exposure to climate hazards based on their precise location, and to assess the physical climate risk exposure of assets in its existing portfolio. PIDG’s investment teams and project sponsors will also leverage the data to inform due diligence and climate risk management and mitigation measures. “We need to ensure that new infrastructure is resilient to the changing climate, especially in the most vulnerable countries,” said Marco Serena, Head of Sustainable Development Impact at PIDG. “Using Moody’s data, we look forward to working with project sponsors and investee companies to understand

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom